Hwaseong, South Korea
Hwaseong, South Korea

Time filter

Source Type

Patent
JW Pharmaceutical Corporation | Date: 2015-04-15

This invention relates to a novel doripenem crystal, a solvate thereof, and a preparation method thereof and, more specifically, to a novel doripenem anhydride crystal, a method of preparing the doripenem anhydride crystal using various solvents, and a solvate of doripenem.


Patent
JW Pharmaceutical Corporation | Date: 2017-05-24

Disclosed is a novel tenofovir disoproxil edisylate salt having the structure of Chemical Formula 1.


Patent
JW Pharmaceutical Corporation | Date: 2015-07-09

Disclosed is a novel tenofovir disoproxil edisylate salt having the structure of Chemical Formula 1.


Patent
JW Pharmaceutical Corporation and Bio Synectics Inc | Date: 2012-08-01

The present invention relates to a nanoparticle of oxaliplatin, which is a water-soluble active substance, a pharmaceutical composition containing the same, and a method for preparing an orally administrable oxaliplatin nanoparticle by emulsifying a lipid mixture solution wherein a solid lipid and a surfactant are mixed in an aqueous mixture solution wherein oxaliplatin and a specific cosolvent are mixed and then removing the solid lipid and the cosolvent using a supercritical fluid gas. By providing oxaliplatin, which is currently available only in injection form for parenteral administration, in the form of a nanoparticle, the present invention allows for the development of orally administrable oxaliplatin which is stable against gastric acid and has improved bioavailability, thereby improving patient compliance through avoiding the inconvenience of injection and greatly reducing medical cost. Since the oxaliplatin nanoparticle can be prepared economically using a relatively inexpensive supercritical fluid producing facility, it can be prepared via a simple process with high yield in commercial scale.


Patent
Jw Pharmaceutical Corporation | Date: 2011-10-14

This invention relates to novel compounds of reverse-turn mimetics, having pyrazino-triazinone as a basic framework, and a method of preparing the same, and the use thereof to treat diseases such as cancer, in particular, acute myeloid leukemia.


Patent
Jw Pharmaceutical Corporation | Date: 2012-08-24

Disclosed is a composition including a pyrazino-triazine derivative and a pharmaceutically acceptable salt thereof. The composition includes a solubilizer or a stabilizer and thus can exhibit very excellent solubility and stability.


Disclosed is a composition comprising a pyrazino-triazine derivative, an isomer thereof or a pharmaceutically acceptable salt thereof. It is very effective for preventing and treating NSCLC.


Patent
JW Pharmaceutical Corporation | Date: 2013-08-21

This invention relates to novel compounds of reverse-turn mimetics, having pyrazino-triazinone as a basic framework, and a method ofpreparing the same, and the use thereofto treat diseases such as cancer, in particular, acute myeloid leukemia.


Disclosed is a composition comprising a pyrazino-triazine derivative, an isomer thereof or a pharmaceutically acceptable salt thereof. It is very effective for preventing and treating NSCLC.


Disclosed is an interferon- (IFN-) fused protein having IFN- fused to a cytoplasmic transduction peptide (CTP). The disclosure relates to a fused protein wherein a CTP, which binds well to cell-membrane barriers and enables translocation into the liver, is genetically fused to a human IFN-, thereby enhancing the conjugation capacity of cell membranes and antiviral activity, inhibiting CTP transport into the cell nucleus, and enhancing the translocation and settlement of the fused protein into the liver and of transduction to the liver tissue. Accordingly, it is possible to develop protein-based medicines effective for preventing or treating various liver diseases associated with viral infection at low doses.

Loading JW Pharmaceutical Corporation collaborators
Loading JW Pharmaceutical Corporation collaborators